16 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Global medtech firm Pall Corporation has tied up with medical device firm CytoMedical Design (CMDG) for exclusive global distribution rights of CMDG's PrepaCyte CB cord blood processing technology. The partnership combines Pall's global leadership in the cord blood field with CMDG's unique product pipeline of highly differentiated cord blood processing technologies.
Each year, thousands of children and adults receive lifesaving transfusions of hematopoietic cord blood stem cells, which are obtained from the umbilical cord at birth, as treatment for blood disorders and cancers.
Pall provides hospitals and cord blood banks with a complete suite of premium products and unique technologies to collect, process, freeze, and transfuse cord blood. CMDG's flagship PrepaCyte CB processing system is an ideal complement to Pall's cord blood product portfolio, combining ease of use with industry-leading performance.
PrepaCyte CB uses proprietary technology to rapidly concentrate cells of interest into volumes as small as 5 mL, while reducing 99 percent of red blood cell contamination. The unique PrepaCyte CB design effectively combines best in class cell recovery with a feature set that offers the flexibility of manual processing with the simplicity of automation.
Mr. Donna M. Regan, director of St. Louis Cord Blood Bank and Cellular Therapy Laboratory states, "In addition to effective reduction of red cell content and recovery of nucleated cells, our early laboratory studies suggest higher potency in PrepaCyte CB prepared products post thaw compared with more widely used processing methods. Subsequently, we adopted the PrepaCyte CB Processing System as our exclusive manufacturing method, and are pleased with the rate of engraftment and successful outcomes demonstrated in the patients who have received these products. We recently received FDA approval of our biologics license application using the PrepaCyte CB Processing System."